Latest Breaking News On - Nikolay savchuk - Page 1 : comparemela.com

Travatrelvir, an Inhibitor of SARS CoV 2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir

356V Travatrelvir, an Inhibitor of SARS-CoV-2 Main.

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics (ONTX) to Merge with Trawsfynydd Therapeutics

i2020 Accelerator Announces the Launch of Gwynant Therapeutics and Celyn Therapeutics to Develop Novel Small Molecules for Oncology Targets

i2020 Accelerator Announces New Investments in Cancer-, Inflammation- and Neurology-focused Therapeutics

Share this article Share this article SAN DIEGO, April 29, 2021 /PRNewswire/ i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced multiple start-up and follow-on investment rounds together with OrbiMed and a start-up investment in a European science-based venture, together with OrbiMed and BioGeneration Ventures (BGV). The proceeds of the follow-ons will be used to further support the three previously funded, oncology-focused companies - Lomond Therapeutics, Eil Therapeutics and Ness Therapeutics and the start-up proceeds will finance three new oncology-focused companies: Bala Therapeutics, Tegid Therapeutics, Padarn Therapeutics as well as an inflammation-focused company, Vyrnwy Therapeutics. The European science-based venture will be known as Brenig Therapeutics and will focus on neurology targets. With this additional financing, the partners continue establishing an oncology, inflammation and neurology Loch group of